The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

Shares of Chimerix CMRX have skyrocketed 323.7% in the past three months following the company’s submission of a new drug ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Scholar Rock is asking the U.S. Food and Drug Administration to approve apitegromab for people with spinal muscular atrophy.

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Many or all of the products on this page are from partners who compensate us when you click to or take an action on their website, but this does not influence our evaluations or ratings. Our ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.

Last year was a surprisingly big one for legal decisions impacting the biotechnology transactions and licensing space. Given that most biotech ...